Drugs / Adenovirus Specific T- Lymphocytes
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06909110 | Apr 2025 → May 2029 expected | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Jessie L. Alexander | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04722029 | Oct 2021 → Oct 2026 expected | adenoviridae infectious disease | Nationwide Children's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04364178 | Aug 2020 → Feb 2023 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Jessie L. Alexander, MD | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adenovirus Specific T- Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04364178 ↗ |
| Modality | Cell therapy | “viral specific T cells” NCT04364178 ↗ |
| Route | Other | “receive ADV-VSTS infusion from haploidentical donors” NCT04722029 ↗ |